Michael J. Mauro MD

Dr. Michael Mauro is Professor of Medicine and leader of the Myeloproliferative Neoplasms Program, Leukemia Service, Memorial Sloan Kettering Cancer Center in New York City. Dr. Mauro’s clinical expertise is in treating patients with chronic myeloid leukemia (CML) as well as other myeloproliferative disorders, including myelofibrosis, polycythemia, and thrombocytosis as well as less common conditions such as eosinophilic and mast cell disorders. His research interests include optimizing therapy response in CML, late and emerging side effects of kinase inhibitors and decision-making amongst therapies for CML and other MPNs. Dr. Mauro’s patient-care philosophy is to offer in-depth explanation regarding diagnoses and to engage in active partnership with his patients and their referring providers to personalize recommendations and monitoring given the chronic nature of the disorders he treats.

Before joining Memorial Sloan Kettering, Dr. Mauro was on the faculty of Oregon Health and Sciences University for 13 years. There he directed the CML clinical trial program and was involved in the early development and sentinel clinical studies of targeted therapy for CML. Dr. Mauro completed both residency and fellowship training at the New York-Presbyterian Hospital/Weill Cornell Medical College in Manhattan and has practiced as a board-certified hematologist for the past 15 years.